News in COVID-19

The TERAVOLT consortium has identified patient- and treatment-related factors associated with an increased risk for death among thoracic cancer patients with COVID-19 infection

Cancer patients with COVID-19 have specific risk factors that may help contribute to a high rate of mortality

Multifactorial reasons involving patients, general practitioners and the healthcare system

Prostate cancer patients using androgen deprivation therapy might have a lower risk of SARS-CoV-2 infection than other cancer patients

Antibodies more often undetectable in patients who received anticancer treatment in the month prior to testing

Balancing pandemic control with providing continued cancer care

Mortality rates do not appear to be associated with any specific type of treatment or comorbidity in this patient group

Treatment delay of at least 2 months reported in only one quarter of patients

An experience in New York City

Research priorities related to incidence, morbidity and mortality of COVID-19 specific to patients with cancer

An accurate COVID-19 screening model could allow early detection and potentially reduce the risk of severe complications and mortality

Patients with cancer and cancer survivors may have a higher risk of COVID-19 than the general population

A metastatic renal cell carcinoma patient who developed COVID-19 may have benefited from treatment with an IL-6 receptor inhibitor

Guidelines commissioned by the French health authorities

Actions taken at a Chinese cancer hospital may have prevented the spread of SARS-CoV-2 and COVID-19

Situation in the first half of March 2020

Analysis of risk factors associated with admission to an intensive care unit, the use of mechanical ventilation or death

Open access: Early data on the transmission of SARS-CoV-2 in Wuhan cancer patients have been published